METHOTREXATE
| Brand name | RASUVO |
|---|---|
| Active ingredient | METHOTREXATE |
| Strength | 12.5MG/0.25ML (12.5MG/0.25ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | July 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8664231 | June 2029 | use U-1442 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.